2型糖尿病治疗:挑战、希望与预期成果
本综述概述了2型糖尿病新型治疗靶点与机制,聚焦降糖效应。讨论了胰岛素新进展(如葡萄糖依赖性智能胰岛素)、脂联素与FGF21等潜力靶点、口服司美格鲁肽及小分子GLP-1受体激动剂,以及减重手术与多受体单分子肽的潜力。这些方法有望扩展有效药物工具箱,优化特定亚组治疗或实现基于个体特征的个性化降糖。
要点
- 新型降糖靶点包括脂联素、FGF21及葡萄糖依赖性智能胰岛素。
- 口服司美格鲁肽已可用,小分子GLP-1受体激动剂初现。
- 多受体单分子肽(GLP-1/GIP/胰高血糖素/PYY)降糖减重优于选择性GLP-1RA。
核心结论
- 新型靶点与机制有望扩展2型糖尿病有效药物工具箱。
- 多受体单分子肽较选择性GLP-1受体激动剂提供更显著降糖和减重。
- 基于个体特征的个性化降糖策略是未来方向。
研究设计与样本
- 综述,检索范围未明确报告。
主要发现
- 葡萄糖依赖性智能胰岛素等新型胰岛素制剂正在开发。
- 脂联素和FGF21等脂肪因子/肝因子具有潜在临床用途。
- 口服司美格鲁肽已可用,小分子GLP-1受体激动剂处于研发早期。
- 减重手术改变肠道激素环境,为多受体单分子肽提供背景。
临床怎么用
- 关注口服GLP-1受体激动剂及小分子药物的临床进展。
- 对特定亚组可考虑多受体单分子肽以强化降糖减重。
- 基于患者个体特征选择降糖药物,推动个性化治疗。
局限性
- 综述未提供系统检索策略及纳入标准。
- 部分新型疗法尚处早期研发阶段,临床证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the successful development of new therapies for the treatment of type 2 diabetes, such as glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 inhibitors, the search for novel treatment options that can provide better glycaemic control and at reduce complications is a continuous effort. The present Review aims to present an overview of novel targets and mechanisms and focuses on glucose-lowering effects guiding this search and developments. We discuss not only novel developments of insulin therapy (eg, so-called smart insulin preparation with a glucose-dependent mode of action), but also a group of drug classes for which extensive research efforts have not been rewarded with obvious clinical impact. We discuss the potential clinical use of the salutary adipokine adiponectin and the hepatokine fibroblast growth factor (FGF) 21, among others. A GLP-1 peptide receptor agonist (semaglutide) is now available for oral absorption, and small molecules activating GLP-1 receptors appear on the horizon. Bariatric surgery and its accompanying changes in the gut hormonal milieu offer a background for unimolecular peptides interacting with two or more receptors (for GLP-1, glucose-dependent insulinotropic polypeptide, glucagon, and peptide YY) and provide more substantial glycaemic control and bodyweight reduction compared with selective GLP-1 receptor agonists. These and additional approaches will help expand the toolbox of effective medications needed for optimising the treatment of well delineated subgroups of type 2 diabetes or help develop personalised approaches for glucose-lowering drugs based on individual characteristics of our patients.
引用
- Nauck MA, Wefers J, Meier JJ, et al. Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. Lancet Diabetes Endocrinol. 2021. PMID: 34181914. doi:10.1016/S2213-8587(21)00113-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。